CARNUMAX

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is a nitrogen mustard β-chloro-nitrosourea compound. It is used in the treatment of brain tumors and various other malignant neoplasms, Multiple myeloma, Hodgkin’s and Non-Hodgkin’s lymphoma.

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is a nitrogen mustard β-chloro-nitrosourea compound. It is used in the treatment of brain tumors and various other malignant neoplasms, Multiple myeloma, Hodgkin’s and Non-Hodgkin’s lymphoma.

 

Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.

Carmustine is administered by intravenous infusion after reconstitution as recommended.

 

INDICATIONS

carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:

  1. Brain tumors—glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.
  2. Multiple myeloma—in combination with prednisone.
  3. Hodgkin’s disease—as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
  4. Non-Hodgkin’s lymphomas—as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

 

 

GenericName Strength Standard Type Packing Pack Size
Carmustine 100 mg IP INJ Vial  1 Vial